Modified RNA Therapeutics for Safe Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy and genetic vaccination methods using DNA face risks such as undesired genomic integration, loss of gene function, and generation of anti-DNA antibodies, along with limited expression levels of peptides or proteins.
Innovation Solution
The use of modified RNA molecules, specifically polynucleotides encoding peptides or proteins related to specific diseases, disorders, or conditions, to treat or prevent these conditions by administering a pharmaceutical composition that includes these RNA molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNA is used for gene therapy, then the therapeutic peptide or protein can be expressed, but there is a risk of undesired genomic integration and generation of anti-DNA antibodies
Solution Approach 1:
The patent extracts the therapeutic function from DNA by using mRNA as the therapeutic agent. The mRNA carries the genetic information needed to produce the therapeutic protein but does not integrate into the genome, thereby separating the beneficial protein production function from the harmful genomic integration risk
Solution Approach 2:
The patent uses mRNA as an intermediary between the genetic information and protein production. Instead of directly introducing DNA that could integrate into the genome, the mRNA serves as a temporary mediator that delivers the coding information to the cytoplasm for protein synthesis without permanent genomic alteration
2Productivity
If DNA is used for gene therapy, then the therapeutic peptide or protein can be expressed, but the expression level is limited
Solution Approach 1:
The patent changes the molecular form from DNA to mRNA, which fundamentally alters the expression dynamics. mRNA can be directly translated by ribosomes in the cytoplasm without requiring nuclear transcription, leading to faster and higher protein expression levels. The patent also employs modified nucleosides in the mRNA to enhance stability and translation efficiency
3Object-affected harmful factors
If mRNA is used for gene therapy, then the risk of genomic integration is minimized, but the stability of mRNA was historically considered too low for efficient therapy
Solution Approach 1:
The patent chemically modifies the mRNA structure by incorporating modified nucleosides (such as pseudouridine, N1-methylpseudouridine, or 5-methylcytidine) at specific positions. These modifications change the physical and chemical parameters of the mRNA, reducing its immunogenicity and increasing its resistance to degradation by cellular nucleases, thereby significantly improving stability while maintaining the low genomic integration risk
Solution Approach 2:
The patent creates a composite mRNA structure by combining modified nucleosides with specific sequence elements (such as 5' cap structures and poly(A) tails) to produce a more stable and functional therapeutic molecule. This composite approach integrates multiple protective and functional elements into a single therapeutic agent
Data Source
AI summary
The present invention relates to a method for treating or preventing a disease, disorder or condition by administration of a polynucleotide, e.g. a modified RNA, encoding a peptide or protein related to this disease, disorder or condition. The present invention also relates to pharmaceutical compositions for use in such method.